Stryker Corp. (SYK) Director Sells $2,095,380.00 in Stock
Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 18,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 11th. The stock was sold at an average price of $116.41, for a total value of $2,095,380.00. Following the sale, the director now owns 193,142 shares of the company’s stock, valued at approximately $22,483,660.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Stryker Corp. (NYSE:SYK) opened at 113.73 on Wednesday. The firm has a 50-day moving average price of $115.18 and a 200 day moving average price of $114.05. Stryker Corp. has a 12-month low of $86.68 and a 12-month high of $123.55. The firm has a market cap of $42.57 billion, a price-to-earnings ratio of 26.81 and a beta of 0.72.
Stryker Corp. (NYSE:SYK) last released its earnings results on Thursday, July 21st. The medical technology company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.33%. The company had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.79 billion. On average, equities research analysts anticipate that Stryker Corp. will post $5.76 earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/stryker-corp-syk-director-sells-2095380-00-in-stock.html
The business also recently declared a quarterly dividend, which will be paid on Monday, October 31st. Investors of record on Friday, September 30th will be issued a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 1.34%. The ex-dividend date of this dividend is Wednesday, September 28th. Stryker Corp.’s dividend payout ratio (DPR) is 35.85%.
Several equities research analysts recently weighed in on the company. Piper Jaffray Cos. boosted their target price on Stryker Corp. from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, July 22nd. Credit Suisse Group AG restated an “outperform” rating and set a $124.00 target price (up previously from $110.00) on shares of Stryker Corp. in a research note on Tuesday, July 19th. Brean Capital restated a “buy” rating and set a $125.00 target price (up previously from $121.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Jefferies Group restated a “hold” rating and set a $120.00 target price (up previously from $113.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Stryker Corp. in a research note on Sunday, July 24th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $114.91.
Hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Stryker Corp. during the first quarter valued at about $298,000. Credit Agricole S A increased its stake in shares of Stryker Corp. by 2.5% in the first quarter. Credit Agricole S A now owns 172,997 shares of the medical technology company’s stock valued at $18,560,000 after buying an additional 4,234 shares during the period. Alpine Partners VI LLC bought a new stake in shares of Stryker Corp. during the first quarter valued at about $282,000. Meiji Yasuda Asset Management Co Ltd. increased its stake in shares of Stryker Corp. by 59.5% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,276 shares of the medical technology company’s stock valued at $673,000 after buying an additional 2,340 shares during the period. Finally, Aviva PLC increased its stake in shares of Stryker Corp. by 1.4% in the first quarter. Aviva PLC now owns 176,356 shares of the medical technology company’s stock valued at $18,921,000 after buying an additional 2,400 shares during the period. 75.49% of the stock is currently owned by institutional investors and hedge funds.
Stryker Corp. Company Profile
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.